Literature DB >> 14695818

Molecular recognition of sub-micromolar inhibitors by the epinephrine-synthesizing enzyme phenylethanolamine N-methyltransferase.

Fiona M McMillan1, Julia Archbold, Michael J McLeish, Joanne M Caine, Kevin R Criscione, Gary L Grunewald, Jennifer L Martin.   

Abstract

The crystal structures of human phenylethanolamine N-methyltransferase in complex with S-adenosyl-l-homocysteine (7, AdoHcy) and either 7-iodo-1,2,3,4-tetrahydroisoquinoline (2) or 8,9-dichloro-2,3,4,5-tetrahydro-1H-2-benzazepine (3, LY134046) were determined and compared with the structure of the enzyme complex with 7 and 7-aminosulfonyl-1,2,3,4-tetrahydroisoquinoline (1, SK&F 29661). The enzyme is able to accommodate a variety of chemically disparate functional groups on the aromatic ring of the inhibitors through adaptation of the binding pocket for this substituent and by subtle adjustments of the orientation of the inhibitors within the relatively planar binding site. In addition, the interactions formed by the amine nitrogen of all three inhibitors reinforce the hypothesis that this functional group mimics the beta-hydroxyl of norepinephrine rather than the amine. These studies provide further clues for the development of improved inhibitors for use as pharmacological probes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14695818     DOI: 10.1021/jm0205752

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Development and validation of a generic fluorescent methyltransferase activity assay based on the transcreener AMP/GMP assay.

Authors:  Tony A Klink; Matt Staeben; Kim Twesten; Andrew L Kopp; Meera Kumar; Rebecca Schall Dunn; Cori A Pinchard; Karen M Kleman-Leyer; Martin Klumpp; Robert G Lowery
Journal:  J Biomol Screen       Date:  2011-09-28

2.  Application of the Goldilocks effect to the design of potent and selective inhibitors of phenylethanolamine N-methyltransferase: balancing pKa and steric effects in the optimization of 3-methyl-1,2,3,4-tetrahydroisoquinoline inhibitors by beta-fluorination.

Authors:  Gary L Grunewald; Mitchell R Seim; Jian Lu; Mariam Makboul; Kevin R Criscione
Journal:  J Med Chem       Date:  2006-05-18       Impact factor: 7.446

3.  Kinetic and pH studies on human phenylethanolamine N-methyltransferase.

Authors:  Qian Wu; Michael J McLeish
Journal:  Arch Biochem Biophys       Date:  2013-09-07       Impact factor: 4.013

4.  Exploring the active site of phenylethanolamine N-methyltransferase with 1,2,3,4-tetrahydrobenz[h]isoquinoline inhibitors.

Authors:  Gary L Grunewald; Mitchell R Seim; Rachel C Regier; Kevin R Criscione
Journal:  Bioorg Med Chem       Date:  2006-11-10       Impact factor: 3.641

5.  Molecular recognition of physiological substrate noradrenaline by the adrenaline-synthesizing enzyme PNMT and factors influencing its methyltransferase activity.

Authors:  Nyssa Drinkwater; Christine L Gee; Munish Puri; Kevin R Criscione; Michael J McLeish; Gary L Grunewald; Jennifer L Martin
Journal:  Biochem J       Date:  2009-08-27       Impact factor: 3.857

6.  Synthesis of 4,5,6,7-tetrahydrothieno[3,2-c]pyridines and comparison with their isosteric 1,2,3,4-tetrahydroisoquinolines as inhibitors of phenylethanolamine N-methyltransferase.

Authors:  Gary L Grunewald; Mitchell R Seim; Seema R Bhat; Marc E Wilson; Kevin R Criscione
Journal:  Bioorg Med Chem       Date:  2007-10-11       Impact factor: 3.641

7.  The reaction mechanism of phenylethanolamine N-methyltransferase: a density functional theory study.

Authors:  Polina Georgieva; Qian Wu; Michael J McLeish; Fahmi Himo
Journal:  Biochim Biophys Acta       Date:  2009-09-03

8.  Structure-Based Drug Design of Bisubstrate Inhibitors of Phenylethanolamine N-Methyltransferase Possessing Low Nanomolar Affinity at Both Substrate Binding Domains1.

Authors:  Jian Lu; Aaron G Bart; Qian Wu; Kevin R Criscione; Michael J McLeish; Emily E Scott; Gary L Grunewald
Journal:  J Med Chem       Date:  2020-11-04       Impact factor: 8.039

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.